Fresenius Medical Care and Humacyte Announce Strategic Global Partnership
June 13, 2018—Fresenius Medical Care and Humacyte, Inc. announced a strategic, global partnership. In addition, Fresenius Medical Care, which is a provider of dialysis products and services, will make a $150 million equity investment in Humacyte, a medical research and development company, to gain a 19% fully diluted ownership stake in the company.
The agreement will support development and regulatory approval of Humacyte’s investigational bioengineered human acellular vessel, Humacyl. Under the terms of the agreement, Fresenius Medical Care will obtain the exclusive global rights to commercialize Humacyl.
According to the companies, Humacyl is currently being investigated for vascular access for hemodialysis to prove it is more effective than current synthetic grafts and fistulas for the treatment of patients with end-stage renal disease. The Humacyl bioengineered blood vessel is currently in phase 3 pivotal trials in the United States and Europe.
After completion of the trials, the companies will seek regulatory approval in both the United States and Europe. Fresenius Medical Care will be responsible for the marketing, sales, and distribution of Humacyl after approval by the relevant health authorities.
The transaction is subject to customary closing conditions, including expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and is expected to close in July 2018, advised the companies.